An Open-label, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343), an Anti-mesothelin Antibody Drug Conjugate, in Pretreated Mesothelin-expressing Advanced Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2017
At a glance
- Drugs Anetumab ravtansine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 11 May 2017 Status changed from not yet recruiting to recruiting.
- 22 Apr 2017 Planned initiation date changed from 1 Mar 2017 to 1 Apr 2017.
- 20 Jan 2017 New trial record